The chronic angina pectoris drugs space claims well-established pharmacologic agents in regular use for decades. The first-line management of chronic angina (stable, microvascular, and variant) is governed by the widespread use of generics including short-acting nitrates, beta-blockers, and calcium channel blockers.
Among the second-line agents, only one medication has had a pronounced influence on the angina market, Gilead’s Ranexa (ranolazine), which held market exclusivity in the US until 2019. Following its launch in the US in 2006, it became the first novel drug for managing angina to enter the US market in two decades. Read more here.